Ischemic Postconditioning on Microvascular Obstruction in Reperfused Myocardial Infarction (POSTRE)
|First Received Date ICMJE||July 9, 2013|
|Last Updated Date||July 9, 2013|
|Start Date ICMJE||October 2011|
|Primary Completion Date||July 2012 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||Microvascular obstruction [ Time Frame: 1 week ]
Microvascular obstruction will be visually defined as a lack of contrast uptake in the core of tissue showing late gadolinium enhancement; the extent of microvascular obstruction will be manually defined and expressed as percentage of LV mass
|Original Primary Outcome Measures ICMJE||Same as current|
|Change History||No Changes Posted|
|Current Secondary Outcome Measures ICMJE
||Infarct size [ Time Frame: 1 week ]
Infarct size will be derived from late gadolinium enhancement and will be considered to be present if signal intensity is >2 standard deviations with respect to a sample of remote non-infarcted myocardium in late gadolinium enhancement imaging
|Original Secondary Outcome Measures ICMJE||Same as current|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Ischemic Postconditioning on Microvascular Obstruction in Reperfused Myocardial Infarction|
|Official Title ICMJE||Effect of Ischemic Postconditioning on Microvascular Obstruction in Reperfused Myocardial Infarction. Results of a Randomized Study in Patients|
Objectives. We will evaluate the effect of ischemic postconditioning (PCON) on microvascular obstruction (MVO) in patients with a first ST-segment elevation myocardial infarction (STEMI) treated with primary angioplasty.
Background. PCON appears as a potentially beneficial tool in STEMI. Its impact on MVO is unknown.
Methods. In a multicenter study, 132 patients with a first STEMI will be randomized to undergo primary angioplasty followed by PCON or primary angioplasty alone (non-PCON). MVO and infarct size (IS) will be quantified (% of left ventricular mass) in a core laboratory analyzing late enhancement cardiovascular magnetic resonance imaging.
In ST-segment elevation myocardial infarction (STEMI) timely coronary reperfusion is the primary therapeutic goal to improve patients' outcome and to reduce left ventricular (LV) infarct size (IS). Unfortunately, despite successful reperfusion of the epicardial blood flow an impairment of microvascular perfusion persists in a significant number of patients, a phenomenon referred to as microvascular obstruction (MVO). This is a multifactorial process caused, among other factors, by microembolization, vasospasm and cells plugging. Cell reperfusion injury related to inflammation as well as to mitochondrial damage provoked by a rapid normalization of the acidotic myocardial environment do play a key role in the pathophysiology of MVO. In recent years MVO has been demonstrated to be a powerful and independent predictor of adverse outcome and larger IS. Cardiovascular magnetic resonance imaging (CMR) has become the state of the art technique for an early non-invasive comprehensive assessment of the structural consequences of STEMI, this including MVO.
Availability of inexpensive and easy-to-implement therapies that could solidly reduce MVO and subsequently optimize the beneficial effects of prompt primary percutaneous intervention would be of utmost importance. In recent years ischemic postconditioning (PCON) has appeared as a promising option. It permits a progressive, rather than brisk, restoration of blood flow to the jeopardized myocardium by means of consecutive cycles of inflation and deflation of the angioplasty balloon used to open the acute coronary occlusion. Previous experimental evidence and preliminary clinical data suggest that this simple strategy exerts, in comparison with the traditional rapid reperfusion using single balloon inflations, a number of protective myocardial effects.
During the last two years the effect of PCON on CMR-derived infarct size in STEMI patients has been evaluated but the results have been controversial. In routine practice, the time window to achieve any additional reduction in IS beyond that derived from timely coronary reperfusion is extremely tight. To the contrary, MVO owing to its pathophysiology and more progressive time course, seems a more suitable and realistic objective to explore the impact of this complementary therapy. Nevertheless the effect of PCON on MVO in STEMI is unknown so far.
In the present study we aim to analyse the effect of PCON on CMR-derived MVO in a randomized series of patients with a first STEMI treated with primary angioplasty.
Study group in patients:
Patients of age ≥18 years admitted to two university hospitals for a first STEMI within the first 12 h of chest pain onset, with ST-segment elevation of >0.1 mV in at least 2 contiguous leads and for whom the clinical decision to treat with percutaneous coronary intervention is made, will be considered for inclusion.
The exclusion criteria will be as follows: documented history of previous infarction; primary percutaneous revascularization not attempted; severe clinical or hemodynamic deterioration; left main stem disease; Thrombolysis In Myocardial Infarction (TIMI) 2-3 or Rentrop collateral flow grade ≥1 upon patient arrival; death, re-infarction, cardiac surgery or severe clinical deterioration before CMR study; patients who deny participation in the registry; any contraindications to CMR.
The institutional ethics committees of the participating institutions has approved the research protocol and written informed consent will be obtained from all subjects. The study will be conducted in accordance with the Declaration of Helsinki.
Reperfusion therapy in patients:
STEMI patients admitted to the institutions participating in the present study will be randomly allocated to either the PCON or the non-PCON group. Randomization will be performed using a computer-generated randomization sequence. In summary, once diagnostic coronary angiography has been carried out and the decision to undertake primary angioplasty has been made, operators will acceed with their personal codes to a web page specifically developed for the present study (Universitat Politecnica, Valencia, Spain) where the patient will be recorded and, then, the study group assignment will be obtained.
Baseline characteristics, clinical data and the TIMI risk score will be prospectively recorded in all cases. The percentage of sum ST-segment resolution 90 min after reperfusion therapy will be determined. Times over the upper reference limit (xURL) of creatine-kinase MB mass will be serially measured upon patient arrival and at 6, 12, 24 and 48 h after reperfusion and the peak value will be recorded.
CMR study in patients:
CMR (1.5-T, Sonata Magnetom, Siemens, Erlangen, Germany) will be performed 1 week after STEMI according to our laboratory protocol. All images will be acquired by a phased-array body surface coil during breath-holds and will be ECG-triggered.
CMR studies will be analyzed in a core lab (INCLIVA, Valencia, Spain) by an experienced observer blinded to all patient data using customized software (QMASS MR, 6.1.5, Medis, Leiden, The Netherlands).
In cine imaging, LV ejection fraction (%), end-diastolic and end-systolic volumes indexes (ml/m2) and mass (g/m²) will be calculated by manual planimetry of endocardial and epicardial borders of all short-axis views (Figure 2).
MVO will be visually defined as a lack of contrast uptake in the core of tissue showing late gadolinium enhancement (Figure 2); the extent of MVO will be manually defined and expressed as percentage of LV mass. In order to avoid artifacts and based on the prognostic value previously demonstrated by our study group, significant MVO will be considered to be present if it is detected in more than one segment using the 17-segment model.
The intra-observer variability for the quantification of all exposed CMR parameters in our core lab has been previously determined and is less than 5%.
The primary endpoint of the present study will be to assess the effect of PCON on the occurrence and extent of MVO in STEMI patients treated with primary angioplasty. The secondary endpoint will be to explore, in the same scenario, the effect of PCON on IS.
The target sample size has been calculated to assess the effect of PCON on the occurrence of MVO measured by CMR imaging. The expected effect was a 50% reduction in the occurrence of MVO with a statistical power of 80% and a probability of a type I error of 0.05 with a 2-sided test. Assuming a drop-out rate of 25%, the total sample consists of 98 patients randomized equally to the two groups. For security reasons we will randomized 132 patients.
Continuous variables will be tested for normal distribution using the one-sample Kolmogorov-Smirnov test. Continuous normally distributed data will be expressed as the mean ± standard deviation and compared using the Student's t-test. Non-parametric data will be expressed as the median with the interquartile range and will be compared with the Mann-Whitney U-test. Group percentages will be compared using the chi-square test or Fisher's exact test where appropriate.
Statistical significance will be considered for two-tailed p <0.05. SPSS 11.0 (SPSS Inc, Chicago, Illinois, USA) was used throughout.
|Study Type ICMJE||Interventional|
|Study Phase||Not Provided|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
|Condition ICMJE||Myocardial Infarction|
|Publications *||Bodi V, Ruiz-Nodar JM, Feliu E, Minana G, Nunez J, Husser O, Martinez-Elvira J, Ruiz A, Bonanad C, Monmeneu JV, Lopez-Lereu MP, Forteza MJ, de Dios E, Hervas A, Moratal D, Gomez C, Mainar L, Sanchis J, Mainar V, Valencia J, Diaz A, Noguera I, Chaustre F, Chorro FJ. Effect of ischemic postconditioning on microvascular obstruction in reperfused myocardial infarction. Results of a randomized study in patients and of an experimental model in swine. Int J Cardiol. 2014 Jul 15;175(1):138-46. doi: 10.1016/j.ijcard.2014.05.003. Epub 2014 May 10.|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Completion Date||July 2012|
|Primary Completion Date||July 2012 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||18 Years and older (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||Spain|
|Removed Location Countries|
|NCT Number ICMJE||NCT01898546|
|Other Study ID Numbers ICMJE||2011/012|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||Fundación para la Investigación del Hospital Clínico de Valencia|
|Study Sponsor ICMJE||Fundación para la Investigación del Hospital Clínico de Valencia|
|Collaborators ICMJE||Instituto de Salud Carlos III|
|PRS Account||Fundación para la Investigación del Hospital Clínico de Valencia|
|Verification Date||January 2013|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP